{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:15:55Z","timestamp":1764576955894,"version":"3.46.0"},"reference-count":34,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The prevalence and the prognostic impact of chronic obstructive pulmonary disease (COPD) and asthma in patients with myeloproliferative neoplasms (MPNs) are unknown. Methods: This retrospective multicenter cohort analyzed the prevalence and prognostic implications of COPD and asthma in 246 patients with essential thrombocythemia (ET) and polycythemia vera (PV). Results: A total of 6.5% and 1.6% patients had COPD or asthma, respectively, without statistically significant differences with respect to disease phenotype. The presence of COPD\/asthma was more frequently associated with active\/prior smoking (p = 0.021) and constitutional symptoms (p = 0.001). After the median follow-up of 47.5 months, the presence of COPD\/asthma was univariately associated with an inferior time to thrombosis (TTT; median 135 vs. 190 months, 95% confidence interval (CI) 1.8\u201329.5, hazard ratio-HR 7.75, p = 0.005), mainly driven by venous (HR 37.3, 95% CI 3.2\u201343.6, p = 0.003) and not arterial events (HR 1.77, 95% CI 0.40\u20137.78, p = 0.445, p = 0.445). Statistically significant interactions existed between COPD\/asthma, female sex (HR 3.94, 95% CI 1.01\u201311.02), ET phenotype (HR 7.1, 95% CI 15.3\u201316.7), JAK2 positive status (HR 4.17, 95% CI 1.04\u20136.9), hydroxyurea use (HR 4.67, 95% CI 1.10\u20137.43), and the presence of other cardiovascular risk factors (HR 8.1, 95% CI 1.55\u201310.72) with overall thrombotic risk (interaction p &lt; 0.050 for all analyses). Finally, the negative effect of COPD\/asthma on TTT persisted in the multivariate analysis (HR 6.54, p = 0.010) independently of older (&gt;60 years) age (p = 0.030) when being adjusted for other clinically meaningful variables. There was no effect of COPD\/asthma on overall survival. Conclusions: These results provide an important signal regarding the potentially inferior outcomes in ET\/PV patients presenting with these common respiratory disorders and may help to further personalize MPN management.<\/jats:p>","DOI":"10.3390\/jcm14238416","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:19:51Z","timestamp":1764328791000},"page":"8416","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of Chronic Obstructive Pulmonary Disease and Asthma in Polycythemia Vera and Essential Thrombocythemia and Its Prognostic Implications"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-305X","authenticated-orcid":false,"given":"Ivan","family":"Krecak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, General Hospital of Sibenik-Knin County, 22000 Sibenik, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"},{"name":"University of Applied Sciences Sibenik, 22000 Sibenik, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-8298","authenticated-orcid":false,"given":"Danijela","family":"Lekovic","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidora","family":"Arsenovic","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center Serbia, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Dabcevic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Ivankovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Holik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dr. Josip Ben\u010devi\u0107 General Hospital, 35000 Slavonski Brod, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Zekanovic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General Hospital Zadar, 23000 Zadar, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Moric Peric","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General Hospital Zadar, 23000 Zadar, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7906-8918","authenticated-orcid":false,"given":"Andrea Anic","family":"Matic","sequence":"additional","affiliation":[{"name":"Clinic for Pulmonary Disorders, University Hospital Center Split, 21000 Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8288-7308","authenticated-orcid":false,"given":"Andrija","family":"Bogdanovic","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Skelin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"},{"name":"University of Applied Sciences Sibenik, 22000 Sibenik, Croatia"},{"name":"Pharmacy Department, General Hospital of Sibenik-Knin County, 22000 Sibenik, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-2040","authenticated-orcid":false,"given":"Marko","family":"Lucijanic","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11899-022-00670-8","article-title":"Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia","volume":"17","author":"Krecak","year":"2022","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00277-023-05426-9","article-title":"Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives","volume":"103","author":"Krecak","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_3","first-page":"541","article-title":"Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms","volume":"21","author":"Krecak","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2346598","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global Burden of Chronic Obstructive Pulmonary Disease Through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_9","unstructured":"GBD 2021 Asthma and Allergic Diseases Collaborators (2025). Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Respir. Med., 13, 425\u2013446."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5588\/ijtld.22.1010","article-title":"The Global Asthma Report 2022","volume":"26","author":"Chakaya","year":"2022","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14779072.2024.2333786","article-title":"Cardiovascular disease and risk in COPD: A state of the art review","volume":"22","author":"Polman","year":"2024","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.chest.2020.11.053","article-title":"The Relationship Between Asthma and Cardiovascular Disease: An Examination of the Framingham Offspring Study","volume":"159","author":"Pollevick","year":"2021","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_14","first-page":"183","article-title":"Erythrocytosis in a patient with chronic obstructive pulmonary disease","volume":"83","author":"Vicari","year":"1998","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-021-00463-x","article-title":"Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera","volume":"11","author":"Nguyen","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1182\/bloodadvances.2020003323","article-title":"Erythrocytosis in the general population: Clinical characteristics and association with clonal hematopoiesis","volume":"4","author":"Wouters","year":"2020","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.thromres.2021.11.025","article-title":"Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients","volume":"209","author":"Holik","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1182\/bloodadvances.2020002843","article-title":"Lung megakaryocytes display distinct transcriptional and phenotypic properties","volume":"4","author":"Yeung","year":"2020","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41408-021-00585-2","article-title":"Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism","volume":"11","author":"Lucijanic","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/thoraxjnl-2013-203996","article-title":"Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: A role for antiplatelet therapy?","volume":"69","author":"Harrison","year":"2014","journal-title":"Thorax"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjh.17130","article-title":"Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study","volume":"193","author":"Knudsen","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"00297-2021","DOI":"10.1183\/23120541.00297-2021","article-title":"Prothrombotic state in patients with stable COPD: An observational study","volume":"7","author":"Kyriakopoulos","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tuleta, I., Skowasch, D., Aurich, F., Eckstein, N., Schueler, R., Pizarro, C., Schahab, N., Nickenig, G., Schaefer, C., and Pingel, S. (2017). Asthma is associated with atherosclerotic artery changes. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186820"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2147\/COPD.S522367","article-title":"Obstructive Airway Disease is Associated with Increased Cardiovascular Disease Risk Independent of Phenotype: Evidence from Two Nationwide Population-Based Studies","volume":"20","author":"Meng","year":"2025","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2147\/COPD.S100533","article-title":"COPD disease severity and the risk of venous thromboembolic events: A matched case-control study","volume":"11","author":"Morgan","year":"2016","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1164\/rccm.201505-0962OC","article-title":"Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study","volume":"193","author":"Portegies","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.thromres.2003.12.003","article-title":"Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD","volume":"112","author":"Ambrosetti","year":"2003","journal-title":"Thromb. Res."},{"key":"ref_28","first-page":"239","article-title":"Risk Factors for Venous Thromboembolism in Chronic Obstructive Pulmonary Disease","volume":"1","author":"Kim","year":"2014","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1183\/09031936.00043313","article-title":"Asthma increases pulmonary thromboembolism risk: A nationwide population cohort study","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-018-0161-9","article-title":"Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/rccm.202210-1941OC","article-title":"Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-based Study","volume":"208","author":"Montani","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12185-022-03454-1","article-title":"Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease","volume":"117","author":"Leiva","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e024350","DOI":"10.1161\/JAHA.121.024350","article-title":"Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis from the IMPACT Trial","volume":"11","author":"Dransfield","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:14:23Z","timestamp":1764576863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":34,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14238416"],"URL":"https:\/\/doi.org\/10.3390\/jcm14238416","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}